A selective ghrelin-receptor pentapeptide studied for pulsatile growth-hormone release with relatively clean hormonal selectivity.
Pre-loaded with a typical Ipamorelin vial. Change any value to match what you actually have.
What published research and laboratory protocols actually document for Ipamorelin. Where a compound has no single microgram figure, we say so rather than inventing one.
| Reported amount | Frequency | Route | Where this figure comes from |
|---|---|---|---|
| 200 mcg – 300 mcg | 1–3 times daily | subcutaneous | Commonly cited in research and laboratory protocol discussions Short half-life leads many research protocols to split daily exposure into one to three subcutaneous pulses. |
| 300 mcg – 10 mg | single / investigational infusion | intravenous | Human IV PK/PD dose-escalation study (Gobburu et al.) Published volunteer study used brief IV infusions across a wide nmol/kg range to model GH response; not a chronic SC template. |
People searching this page also look for: ipamorelin peptide dosage, ipamorelin peptide dosage per day, cjc 1295 ipamorelin peptide dosage, ipamorelin peptide dosage for men, cjc ipamorelin peptide dosage, ipamorelin peptide dosage for women, ipamorelin peptide benefits side effects dosage, peptide calculator cjc 1295 ipamorelin dosage.
Ipamorelin is a pentapeptide growth hormone secretagogue that stimulates the ghrelin receptor (GHS-R1a). Researchers value it because early work suggested strong GH release with comparatively little stimulation of ACTH and cortisol at doses that still moved GH, an important selectivity contrast versus older GHRP scaffolds. Human pharmacokinetic-pharmacodynamic modeling and multiple preclinical growth studies established the core profile: a short circulating half-life, a discrete GH pulse, and dose-responsive somatotropic signaling. Ipamorelin remains a frequent reference compound in GH-axis, body-composition, and secretagogue-combination research. In research-supply contexts it is almost always handled as a lyophilized peptide for subcutaneous investigation. Content on this page is educational and research-use-only; ipamorelin is not an FDA-approved therapeutic product.
Ipamorelin binds the growth hormone secretagogue receptor GHS-R1a, the same receptor activated by ghrelin. Receptor activation on pituitary somatotrophs promotes GH vesicle release. Because the peptide is relatively selective, experimental comparisons often highlight GH elevation with muted collateral HPA-axis activation versus earlier GHRPs. The short half-life produces a pulse-like GH exposure rather than a flat, prolonged elevation.
growth hormone axis research · ghrelin receptor pharmacology · body composition and recovery models · bone growth preclinical research · secretagogue combination studies
Endocrinology labs, sports-medicine research groups, and peptide pharmacology teams use ipamorelin when they need a selective GH secretagogue comparator. It also appears in protocol papers exploring GHRH-analogue plus GHRP co-administration. The audience is research personnel, not patients seeking treatment advice.
Keep lyophilized vials cold, dry, and protected from light. After reconstitution with bacteriostatic water, refrigerate and avoid repeated warm-cold cycling; many labs aliquot to limit handling stress.
Ipamorelin is frequently discussed alongside GHRH analogues such as CJC-1295 (with or without DAC) or sermorelin because the two classes hit complementary nodes of GH release. Research stacks aim to amplify pulse amplitude while preserving physiologic timing. Literature comparisons sometimes include other GHRPs (GHRP-2, GHRP-6) when ranking selectivity and side-effect profiles.
The questions people actually search for, answered plainly.
Laboratory and secondary research summaries most often cite roughly 200–300 mcg per subcutaneous administration, sometimes repeated up to two or three times daily because of the short half-life. Published human PK work used IV mcg/kg infusions rather than a single universal SC chart.
A practical research reconstitution is 2–3 mL bacteriostatic water in a 5 mg or 10 mg vial. Example: 5 mg + 2.5 mL yields 200 mcg per 10 units on a U-100 syringe. Confirm arithmetic against your exact vial label.
Daily totals in informal research discussions often land near 200–900 mcg/day when split across one to three injections. Those figures are commonly cited reference ranges, not individualized medical directions.
Charts usually convert vial strength and diluent volume into mcg-per-tick-mark on an insulin syringe, then list once-, twice-, or thrice-daily pulse schedules. Use them only as research math aids.
Human pharmacokinetic modeling after IV infusion reported a terminal half-life around two hours, which explains multi-pulse experimental schedules.
In research settings it is commonly examined with GHRH analogues (for example CJC-1295/sermorelin) to probe synergistic GH release. Stack design belongs in controlled research protocols.
Foundational selectivity work reported minimal ACTH/cortisol stimulation at GH-releasing doses relative to several earlier secretagogues, which is a major reason it is studied as a cleaner GHS tool compound.
Peer-reviewed human data center on parenteral routes (IV infusion historically; SC in later research practice). Oral bioavailability is not the standard research route.
Primary literature on Ipamorelin. Open access where available.
Every citation above was programmatically checked against the NCBI PubMed database. Titles shown are the official indexed titles, not paraphrases.
Our support assistant walks through reconstitution, syringe units, storage, and how to read a Certificate of Analysis. Free, no account.
Read the guides